Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Trial Profile

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Amino acids; Fludeoxyglucose F-18; Gallium 68-DOTATATE
  • Indications Paraganglioma; Phaeochromocytoma
  • Focus Therapeutic Use
  • Acronyms 177Lu-DOTATATE trial
  • Most Recent Events

    • 30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.
    • 30 Jun 2022 According to a Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified. Company restarted screening and enrollment for clinical trials with Lutathera in the US and Canada.
    • 05 May 2022 According to Novartis media release, status changed from recruiting to suspended as Novartis is putting a temporary hold on screening and enrollment for Lutathera clinical trials in the US and Canada.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top